الفهرس 
LEVEL OF EVIDENCE AND CLASSIFICATION OF RECOMMENDATIONSOnly 14 pages are availabe for public view
 |  | from | 175 |  |  |
| | | from | 175 | | |
Abstract
Lower extremity arterial occlusive disease (LEAOD) is one of the most challenging problems facing vascular specialists, not only because of the complexity of the disease in the legs, but also because of the associated medical comorbidity of patients afflicted with this disease. Up to 60% of patients with peripheral arterial disease (PAD) have associated coronary artery disease (CAD) or cerebrovascular disease (CVD) and are at risk of myocardial infarction (MI), stroke, and cardiovascular death. (Pennywell et al 2014)
Critical limb ischaemia (CLI) is the most severe form of peripheral vascular disease where there is inadequate blood flow to a limb to maintain reasonable metabolic requirement of the tissues at rest. Eventual loss of limb is the feared sequelae of CLI. The Trans-Atlantic Inter-Society Consensus (TASC) defines critical limb ischaemia (CLI) as persistently recurring ischaemic rest pain requiring opiates for at least 14 days, foot or toe ulceration or gangrene and ankle-brachial index (ABI ) < 0.40, toe pressure (TP) <30 mmHg, systolic ankle pressure < 50 mmHg, flat pulse volume waveform and absent pedal Pulses. (Pua et al., 2008)
The use of drug-eluting balloons (DEB) for treatment of femoro-popliteal artery obstructions has become widespread in recent years. The possibility to deliver a drug into the arterial wall with sustained anti-proliferative effects, without leaving behind metal scaffolding, seems very promising. The current generation of drug-eluting balloons differs in the formulation of the drug, technique of coating, and the elution excipients. (De Vries et al., 2013)
Lower extremity arterial occlusive disease (LEAOD) is one of the most challenging problems facing vascular specialists, not only because of the complexity of the disease in the legs, but also because of the associated medical comorbidity of patients afflicted with this disease. Up to 60% of patients with peripheral arterial disease (PAD) have associated coronary artery disease (CAD) or cerebrovascular disease (CVD) and are at risk of myocardial infarction (MI), stroke, and cardiovascular death. (Pennywell et al 2014)
Critical limb ischaemia (CLI) is the most severe form of peripheral vascular disease where there is inadequate blood flow to a limb to maintain reasonable metabolic requirement of the tissues at rest. Eventual loss of limb is the feared sequelae of CLI. The Trans-Atlantic Inter-Society Consensus (TASC) defines critical limb ischaemia (CLI) as persistently recurring ischaemic rest pain requiring opiates for at least 14 days, foot or toe ulceration or gangrene and ankle-brachial index (ABI ) < 0.40, toe pressure (TP) <30 mmHg, systolic ankle pressure < 50 mmHg, flat pulse volume waveform and absent pedal Pulses. (Pua et al., 2008)
The use of drug-eluting balloons (DEB) for treatment of femoro-popliteal artery obstructions has become widespread in recent years. The possibility to deliver a drug into the arterial wall with sustained anti-proliferative effects, without leaving behind metal scaffolding, seems very promising. The current generation of drug-eluting balloons differs in the formulation of the drug, technique of coating, and the elution excipients. (De Vries et al., 2013)